Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CellCept in Pemphigus Vulgaris
NCT00683930Phase 3Completed
- Sponsor
- Roche
- Start
- May 2004
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of mycophenolate mofetil in pemphigus vulgaris (PV) (3 arms), sponsored by Roche. Primary endpoint: Percentage of Patients Achieving Responder Status at Week 52. Started May 2004; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT00683930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00683930.